REGENERON PHARMACEUTICALS, INC. — 13F Holdings & Portfolio
CIK 872589 · latest 13F-HR filed 2026-05-08
REGENERON PHARMACEUTICALS, INC. manages $47.9M in 13F-reported U.S. long-equity assets across 2 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are NTLA (99.14%), Adicet Bio, Inc. (0.86%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 0 new positions, exited 0, added to 1, and trimmed 1.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$47.9M
Long-equity book
2
Distinct positions
2026-03-31
Filed 2026-05-08
+0 / −0 / ↑1 / ↓1
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | Intellia Therapeutics, Inc. | NTLA | 45826J105 | $47.5M | 99.14% | 3,702,995 | SH |
| 2 | Adicet Bio, Inc. | — | 007002108 | $412.1K | 0.86% | 60,511 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-08 | $47.9M | 2 | 0001104659-26-057922 |
| 2025-12-31 | 2026-02-06 | $33.8M | 2 | 0001104659-26-011601 |